Literature DB >> 33268518

Vaccines That Reduce Viral Shedding Do Not Prevent Transmission of H1N1 Pandemic 2009 Swine Influenza A Virus Infection to Unvaccinated Pigs.

Sharon M Brookes1, Ian H Brown1, Bryan Charleston2, Sarah Gilbert3, Helen E Everett4, Pauline M van Diemen1, Mario Aramouni3, Andrew Ramsay1, Vivien J Coward1, Vincent Pavot3, Laetitia Canini5, Barbara Holzer2, Sophie Morgan2, Mark E J Woolhouse5, Elma Tchilian2.   

Abstract

Swine influenza A virus (swIAV) infection causes substantial economic loss and disease burden in humans and animals. The 2009 pandemic H1N1 (pH1N1) influenza A virus is now endemic in both populations. In this study, we evaluated the efficacy of different vaccines in reducing nasal shedding in pigs following pH1N1 virus challenge. We also assessed transmission from immunized and challenged pigs to naive, directly in-contact pigs. Pigs were immunized with either adjuvanted, whole inactivated virus (WIV) vaccines or virus-vectored (ChAdOx1 and MVA) vaccines expressing either the homologous or heterologous influenza A virus hemagglutinin (HA) glycoprotein, as well as an influenza virus pseudotype (S-FLU) vaccine expressing heterologous HA. Only two vaccines containing homologous HA, which also induced high hemagglutination inhibitory antibody titers, significantly reduced virus shedding in challenged animals. Nevertheless, virus transmission from challenged to naive, in-contact animals occurred in all groups, although it was delayed in groups of vaccinated animals with reduced virus shedding.IMPORTANCE This study was designed to determine whether vaccination of pigs with conventional WIV or virus-vectored vaccines reduces pH1N1 swine influenza A virus shedding following challenge and can prevent transmission to naive in-contact animals. Even when viral shedding was significantly reduced following challenge, infection was transmissible to susceptible cohoused recipients. This knowledge is important to inform disease surveillance and control strategies and to determine the vaccine coverage required in a population, thereby defining disease moderation or herd protection. WIV or virus-vectored vaccines homologous to the challenge strain significantly reduced virus shedding from directly infected pigs, but vaccination did not completely prevent transmission to cohoused naive pigs. © Crown copyright 2021.

Entities:  

Keywords:  influenza A; pH1N1; pig; transmission; vaccine

Year:  2021        PMID: 33268518      PMCID: PMC7851569          DOI: 10.1128/JVI.01787-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Strategies for containing an emerging influenza pandemic in Southeast Asia.

Authors:  Neil M Ferguson; Derek A T Cummings; Simon Cauchemez; Christophe Fraser; Steven Riley; Aronrag Meeyai; Sopon Iamsirithaworn; Donald S Burke
Journal:  Nature       Date:  2005-08-03       Impact factor: 49.962

2.  Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone.

Authors:  E I Budowsky; E A Friedman; N V Zheleznova; F S Noskov
Journal:  Vaccine       Date:  1991-06       Impact factor: 3.641

3.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Authors:  Sarah C Gilbert; Jörg Schneider; Carolyn M Hannan; Jiang Ting Hu; Magdalena Plebanski; Robert Sinden; Adrian V S Hill
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Animal Models for Influenza A Virus Infection Incorporating the Involvement of Innate Host Defenses: Enhanced Translational Value of the Porcine Model.

Authors:  Sofie M R Starbæk; Louise Brogaard; Harry D Dawson; Allen D Smith; Peter M H Heegaard; Lars E Larsen; Gregers Jungersen; Kerstin Skovgaard
Journal:  ILAR J       Date:  2018-12-31

5.  Efficacy in pigs of inactivated and live attenuated influenza virus vaccines against infection and transmission of an emerging H3N2 similar to the 2011-2012 H3N2v.

Authors:  Crystal L Loving; Kelly M Lager; Amy L Vincent; Susan L Brockmeier; Phillip C Gauger; Tavis K Anderson; Pravina Kitikoon; Daniel R Perez; Marcus E Kehrli
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

6.  Development and evaluation of a one-step real-time RT-PCR assay for universal detection of influenza A viruses from avian and mammal species.

Authors:  Alexander Nagy; Veronika Vostinakova; Zuzana Pirchanova; Lenka Cernikova; Zuzana Dirbakova; Miroslav Mojzis; Helena Jirincova; Martina Havlickova; Adam Dan; Krisztina Ursu; Stefan Vilcek; Jitka Hornickova
Journal:  Arch Virol       Date:  2010-03-13       Impact factor: 2.574

Review 7.  Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine.

Authors:  Lynda Coughlan; Peter Palese
Journal:  Cell Host Microbe       Date:  2018-07-11       Impact factor: 21.023

8.  Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.

Authors:  L Coughlan; S Sridhar; R Payne; M Edmans; A Milicic; N Venkatraman; B Lugonja; L Clifton; C Qi; P M Folegatti; A M Lawrie; R Roberts; H de Graaf; P Sukhtankar; S N Faust; D J M Lewis; T Lambe; Avs Hill; S C Gilbert
Journal:  EBioMedicine       Date:  2018-02-15       Impact factor: 8.143

9.  Effective induction of high-titer antibodies by viral vector vaccines.

Authors:  Simon J Draper; Anne C Moore; Anna L Goodman; Carole A Long; Anthony A Holder; Sarah C Gilbert; Fergal Hill; Adrian V S Hill
Journal:  Nat Med       Date:  2008-07-27       Impact factor: 53.440

10.  The global antigenic diversity of swine influenza A viruses.

Authors:  Nicola S Lewis; Colin A Russell; Pinky Langat; Tavis K Anderson; Kathryn Berger; Filip Bielejec; David F Burke; Gytis Dudas; Judith M Fonville; Ron Am Fouchier; Paul Kellam; Bjorn F Koel; Philippe Lemey; Tung Nguyen; Bundit Nuansrichy; Js Malik Peiris; Takehiko Saito; Gaelle Simon; Eugene Skepner; Nobuhiro Takemae; Richard J Webby; Kristien Van Reeth; Sharon M Brookes; Lars Larsen; Simon J Watson; Ian H Brown; Amy L Vincent
Journal:  Elife       Date:  2016-04-15       Impact factor: 8.140

View more
  3 in total

1.  Inherent Serum Inhibition of Influenza Virus Neuraminidases.

Authors:  Amanda L Skarlupka; Ted M Ross
Journal:  Front Vet Sci       Date:  2021-08-02

2.  Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Pedro M Folegatti; Daniel Jenkin; Susan Morris; Sarah Gilbert; Denny Kim; James S Robertson; Emily R Smith; Emalee Martin; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

3.  Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs.

Authors:  Eleni Vatzia; Elizabeth R Allen; Tanuja Manjegowda; Susan Morris; Adam McNee; Veronica Martini; Reshma Kaliath; Marta Ulaszewska; Amy Boyd; Basudev Paudyal; Veronica B Carr; Tiphany Chrun; Emmanuel Maze; Ronan MacLoughlin; Pauline M van Diemen; Helen E Everett; Teresa Lambe; Sarah C Gilbert; Elma Tchilian
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.